IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Century Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.47+0.10 (+7.30%)
Close on Oct 19, 2026
- Market cap
- $302.49M
- P/E (TTM)
- –
- Dividend yield
- –
Century Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Century Therapeutics | Industry median |
|---|---|---|
| Market Cap | $266.18M | $164.85M |
| Enterprise Value | $146.47M | $87.06M |
| PB Ratio | 1.15 | 2.03 |
| P/TBV Ratio | 1.34 | 2.31 |
Income (trailing twelve months)
| Measure | Century Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$116.99M | -$21.44M |
| Net Income | -$109.79M | -$22.46M |
| EBITDA | -$116.99M | -$16.91M |
| EPS (Diluted) | -$0.90 | -$0.83 |
Returns
| Measure | Century Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -49.7% | -53.1% |
| Return on Assets (ROA) | -38.4% | -41.0% |
| Return on Invested Capital (ROIC) | -112.7% | -32.0% |
| Return on Capital Employed (ROCE) | -43.0% | -37.8% |
Growth
| Measure | Century Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | 175.9% | 2.25% |
Balance sheet
| Measure | Century Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $119.71M | $62.42M |
| Net Cash (Debt) | $119.71M | $15.68M |
| Net Cash Per Share | $0.66 | $0.66 |
| Equity (Book Value) | $232.35M | $48.79M |
| Book Value Per Share | $1.28 | $1.36 |
| Tangible Book Value | $198.15M | $23.06M |
| Working Capital | $109.70M | $75.77M |
Financial position
| Measure | Century Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 8.28 | 3.30 |
| Quick Ratio | 7.94 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Century Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$86.76M | -$12.35M |
| Capital Expenditures | -$1.33M | -$1.06M |
| Free Cash Flow | -$88.09M | -$20.28M |
| FCF Per Share | -$0.49 | -$0.42 |
Efficiency
| Measure | Century Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.41M | -$703.34K |
| Employee Count | 78 | 74 |
Dividends and yields
| Measure | Century Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -41.2% | -22.7% |
| FCF Yield | -33.1% | -9.07% |
| Buyback Yield | -0.23% | -0.73% |
| Shareholder Yield | -0.23% | 0.00% |
Shares
| Measure | Century Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 181,075,000 | 58,179,650 |
| Shares Change (YoY) | 67.3% | 11.1% |
| Shares Change (QoQ) | 0.25% | 0.54% |
| Float | 174,223,000 | 49,173,100 |
| Shares Held by Insiders | 3.78% | 11.6% |
| Shares Held by Institutions | 87.3% | 59.4% |
Scores
| Measure | Century Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -2.10 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Century Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.